Skip to main content

Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity



Thrombosis plays an important role in the Coronavrus Disease 2019 (COVID-19) infection-related complications such as acute respiratory distress syndrome and myocardial infarction. Multiple factors such as oxygen demand injuries, endothelial cells injury related to infection, and plaque formation.

Main body

Platelets obtained from the patients may have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, showing that the increased activation potential recommends platelet can be hyper-activated in severely ill SARS-CoV-2 cases. Platelets contain multiple receptors that interact with specific ligands. Pathogen’s receptors such as Toll-like receptors (TLRs), NOD-like receptor, C-type lectin receptor family, glycoprotein (GP) such as GPαIIbβ3 and GPIbα which allow pathogens to interact with platelets. Platelet TLRs and NOD2 are involved in platelet activation and thrombosis. Accordingly, TLRs are critical receptors that could recognize various endogenous damage-associated molecular patterns and exogenous pathogen-associated molecular patterns (PAMPs). TLRs are considered as important components in the activation of innate immunity response against pathogenic and non-pathogenic components like damaged tissues. TLRs-1,-2,-4,-6,-7 expression on or within platelets has been reported previously. Various PAMPs were indicated to be capable of binding to platelet-TLRs and inducing both the activation and promotion of downstream proinflammatory signaling cascade.


It is possible that the increased TLRs expression and TLR-mediated platelets activation during COVID-19 may enhance vascular and coronary thrombosis. It may be hypothesized using TLRs antagonist and monoclonal antibody against P-selectin, as the marker of leukocyte recruitment and platelet activation, besides viral therapy provide therapeutic advances in fighting against the thrombosis related complications in COVID-19.


Platelets are key cells in thrombosis, as a physiological process in which vessel damage consequently results in clot formation. However, in pathological situation, these may lead to vessel occlusion, ischemia, and tissue damages [1]. Moreover, endothelial cells injury leads to subendothelial exposure, platelet aggregation, and clot formation [2]. Viruses could attach to platelet-plasma or endosomal membrane surface receptors and then active platelets via specific, signaling cascades [3]. Engagement of surface Fc receptors that bind to immunoglobulin-coated virions could also activate platelets [4]. Platelets express pattern recognition receptors (PRRs), including TLR, Nod-like receptor, and C-type lectin receptors that has a critical role in recognition of damage-associated molecular patterns (DAMPs) as well as exogenous pathogen-associated molecular patterns (PAMPs), which is referred as virus associated molecular patterns (VAMPs) in cases of viruses [5,6,7]. TLRs are critical molecules in the initiation of innate and adaptive immune responses, and may be expressed either on cell surfaces (TLRs-1,-2,-4,-5,-6,-10) or in the endosome compartment (TLRs-3,-7,-8,-9) [8,9,10,11]. These receptors attachment to DAMP and PAMP can active intracellular pathways such as production of proinflammatory cytokines [12,13,14,15]. Platelets endocytose virions, after attachment of TLRs to their released lysosomal ligands i.e., ssRNA, dsRNA, CpG DNA downstream signaling lead to platelet activation and granule release, expose P-selectin, and finally form platelet leukocyte aggregates (PLAs) [16].

It is likely that thrombosis due to the activation of the innate immune system through TLRs could induce some subsequent vascular occlusive events [17, 18]. Local release of DAMPs during acute myocardial infarction (AMI) is known as an event that triggers proinflammatory TLR activation, which can subsequently aggravate myocardial injury [19, 20]. Notably, various PAMPs are capable of inducing platelet activation [21]. Treatment with pam3CSK4, which is a pharmaceutical agonist of TLR1/TLR2 ligand, could directly induce platelets activation; platelet’s adhesion, aggregation, degranulation, and interaction with leukocytes [12]. Human platelets express TLRs-1,-2,-4,-6 as well as 7 receptors [22,23,24]. As well, a recent study showed SARS-CoV-2 spike protein could interact with TLRs, especially TLR-4 [25]. It is possible that alternative platelet activation’s pathways may promote recurrent thrombosis in COVID-19 patients.

By considering the presence of some TLRs and NOD2 in platelets, these molecules may play roles in platelet activation and thrombosis in the onset of myocardial infarctions during SARS-CoV-2 infection.

Platelet activation and P selectin

P-selectin (CD62P) (formerly known as PADGEM and GMP140), is an integral protein that acts as a cell adhesion molecule on the surfaces of the activated endothelial cells as well as the activated platelets to bind to neutrophil and monocytes [26,27,28]. The soluble form of P-selectin lacks the transmembrane domain that appears to be produced from alternative splicing of pre mRNA [29]. Of note, the primary ligand for P-selectin is P-selectin glycoprotein ligand-1 (PSGL1), which is expressed on almost all leukocytes. P-selectin leads to leukocyte rolling and then acts as the first agent for the leukocyte recruitment [30]. P-selectin is mostly synthesized in endothelial cells and megakaryocyte and then stored in weibel-palade bodies and α-granules, respectively [31]. Moreover, it plays an essential role in the initial recruitment of leukocytes to the site of injury during inflammation. During this process, inflammatory mediators such as interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α), and LPS result in the P-selectin secretion from endothelial cells. Although LPS and TNF-a increase both mRNA and protein levels in murine models, they cannot affect mRNA expression in human endothelial cells, while IL-4 increases P-selectin mRNA in both of them [32,33,34]. It was shown that the P-selectin overexpression in endothelial cells leads to leukocyte rolling via PSGL-1 and acts as the first agent for the leukocyte recruitment to inflammatory sites [35]. Additionally, P-selectin activates monocyte to produce tissue factor (TF), which is the main activator of extrinsic coagulation cascade [36]. It is noteworthy that the P-selectin-mediated leukocyte recruitment into the lungs during acute respiratory distress syndrome (ARDS) and infusion of anti P-selectin (monoclonal antibody) reduce the severity of ARDS [37]. Soluble P-selectin is parallel to platelet’s activation and thrombosis elevated in ARDS cases compared to control and also in non-survivors compared to survivors [38, 39].

Due to the high prevalence rate of thrombotic complications among COVID-19 patients, a possible role has been suggested for P-selectin in activating intravascular coagulation [39, 40].

Platelet receptors activation

Platelets included a cytoskeleton and dense tubular system, few mitochondria, storage granules; glycogen, δ and α granules and peroxisomes. The α-granules contain proteins for the platelets hemostatic functions, such as, thrombospondin, platelet factor-4, von willebrand factor (VWF), fibrinogen, P-selectin, CD40 ligand (CD154), β-thromboglobulin, platelet derived growth factor (PDGF), FV, GP IIb/IIIa, δ granules contain nucleotides (ADP and ATP), serotonin, histamine, pyrophosphate, and calcium. Upon platelet activation, granules contents are transfer to platelet membrane or release to extracellular space to further promote platelet adhesion and activation [41].

A wide variety of mobile transmembrane receptors covers the platelet membrane. Many of these receptors are expressed by other cell types, but some are only expressed on platelets. It is well known that the major platelet receptors have a prominent role in the hemostatic function of platelets, allowing platelets have specific interactions and functional responses with vascular adhesive proteins. The platelet receptors including thrombin receptors (PAR-1 and PAR-4), ADP receptors (P2Y1 and P2Y12), Chemokine receptors (CXCR1 and CXCR4), TxA2 receptor, VWF receptor (GPIIb/IIIa), integrins (αIIbβ3, α2β1, α5β1, α6β1, αVβ3), Glycoprotein (GP) Ib/IX/V, Toll-like receptors, proteins belonging to the immunoglobulin superfamily (GP VI, FcγRIIA), P-selectin, CD63, CD36, P-selectin ligand 1, TNF receptor type [3, 6, 9, 42]. (Fig. 1).

Fig. 1
figure 1

Different predominant platelet receptors and their physiological role. PAR1/PAR4; Adhesion, spreading, and secretion, GPIb-IX-V complex;Initiation of platelet recruitment, TXA2R;Platelet aggregation, TLR; Inflammatory response, P2Y1 and P2Y12; Amplification of aggregation, GPIIb/IIIa; Platelet aggregation, CD36;Aggregation, stabilization of aggregates, P-selectin; Clot formation with leukocytes, GPVI; Platelet aggregation, P-selectin interacting with PSGL-1 on leukocyte, CXCR4; Platelet activation (P-selectin expression, adhesion [41]

Platelet receptors and viral infection

Platelets contain multiple receptors that interact with specific ligands. Pathogen’s receptors such as TLRs, NOD like receptors, C-type lectin receptor family, FcγRIIA, glycoprotein (GP) αIIbβ3, GPIbα which allow pathogens to interact with platelets [3, 23, 42, 43]. Innate immune receptors participate in platelet-leukocyte interactions. Pathogens or their products directly or indirectly induce platelet activation. The complex of IgG-pathogen binds to IgG receptor FcγRIIA then leads to pathogen engulfment and reduction. Platelet CD40L expression allows them to interact with different immune cells. In addition, CD40L may be cleaved into a soluble form (sCD40L) that enhances platelet activation, aggregation, and platelet-leukocyte attachment. Platelets can carry and eliminate pathogens, and via the expression of TLRs they can bind bacterial LPS and activate neutrophils, inducing NETs formation. Intact platelet MHC class I molecules are located intracellular but upon activation are expressed and can activate antigen-specific CD8+ T cells. In contrast, the MHC class I molecules on the surface of resting platelets are denatured and lead to CD8+ T cell inhibition. Platelets contain many proinflammatory and anti-inflammatory cytokines and chemokines and, upon activation, can release them to the extracellular space. The culmination of these events makes platelets a main immunomodulatory host (Fig. 2) [6].

Fig. 2
figure 2

Platelet immune receptors and functions. Schematic representation of the crucial roles of platelets in inflammatory processes. 1) The binding of IgG-pathogen complex to IgG receptor (FcγRIIA) leads to pathogen engulfment and reduction. 2,3) Platelets can express TLRs that bind to bacterial LPS and specific PAMPs. 4) Interaction of platelet CD40L with different immune cells has an important role in leukocyte recruitment and activation. 5) Platelet MHC class I molecules are located in intracellular space but upon activation these molecules expressed on cell membrane and can activate antigen-specific CD8+ T cells. 6) Activation of TLR7 that distinguish ssRNAs leads to P-selectin as a platelet activation marker and CD154 receptor. 7) Platelets contain many proinflammatory and anti-inflammatory cytokines and chemokines and be can released from these cells to the extracellular space. 8) Soluble form of CD40L (sCD40L) enhances platelet activation, aggregation, and platelet-leukocyte attachment [3, 6, 42]

Moreover, platelet’s activation during the process of viral exposure by hepatitis virus, adenovirus, Dengue, and HIV-1 was reviewed in a study by Flaujac et al. [44]. Despite the fact that different viruses could activate platelets, its occurrence remained less clear so far. Platelet’s activation after viral exposure can be summarized in the following 3 categories: 1:Viruses may directly bind to surface proteins and then activate platelets via downstream specific signaling cascades [3], 2: Immunoglobulin-coated virions could activate platelets via engagement of surface Fc receptors [4], and 3: TLRs play a role in some viruses (i.e., encephalomyocarditis virus) [45].

TLRs and platelet activation

Viral ss-RNA of SARS-COV-2 is sensed by TLR-3, TLR-7, and TLR-8 proteins [46]. Previous studies have shown the internalization and clearance of ssRNA viruses such as influenza and HIV by platelets [13, 22, 47]. TLR7 is expressed in platelets at both the protein [48] and mRNA level [49, 50]. Platelets can also internalize pathogens (i.e., bacteria and viruses) when an interaction with endosomal TLRs (e.g., TLR-7 and TLR-9) occurs [12, 13, 51]. Upon viral infection, platelets are activated through TLR7 that change their phenotype and induce the formation of platelet-neutrophil aggregates. After the lysosomal degradation of the internalized viral particles, ssRNA genome attaches to endosomal TLR-7. Virus, via ssRNA may mediate platelets’ activation through TLR-7, leading to degranulation, change of phenotype and aggregates with neutrophils. This mechanism is likely to participate in antiviral immunity since TLR-7-depleted mice had an increase in mortality [16, 45, 52]. The activation of TLR-7 pathway leads to platelet’s degranulation of P-selectin, which consequently results in platelet’s activation as well as overexpression of CD40 ligand CD40L/CD154. These aggregates ultimately lead to platelet-neutrophil aggregates and inflammation and thrombocytopenia without promotion of thrombosis [45]. Platelets stimulate with TLR-3 agonists that lead to α-granule-stored factors translocation (P-selectin and CD40L) to cell surface and induce procoagulant responses to traditional agonists such as thrombin [53, 54]. As TLR-7 recognizes viral ss-RNA, it may be important in platelet’s activation related to SARS-CoV-2 infection. Platelet express TLR-4 that recognize PAMPs and DAMPs ligands [55]. DAMPs like histones, high mobility group box 1 (HMGB1) and heat shock proteins (HSPs) that released during host tissue injury or viral infection can bound to neutrophil extracellular traps, (NETs), trigger both prothrombotic and procoagulant platelet-mediated responses, partly by interacting with TLR4 [56,57,58,59].

It is possible that TLRs-mediated platelets activation in COVID-19 patients subsequently exaggerates both vascular and coronary thrombosis and it may also be related to myocardial injury [23, 24].

Role of platelets in COVID-19 infection

Platelets maintain the integrity of the alveolar capillaries in normal situation, but in pathologic situation, they may contribute into causing lung injury [60]. In addition, platelet-endothelial interactions and platelet-leukocyte aggregation contribute into the pathogenesis of acute lung injury [61,62,63]. Moreover, in viral infections, thrombocytopenia, interactions with leukocytes, and platelet’s secretion may lead to the protective or injurious immune effects [64].

In patients with COVID-19, thrombocytopenia rate is estimated at about 5–41.7%, and typically it has a mild form (100–150 × 109/L) [65,66,67,68]. Additionally, severe thrombocytopenia, which may have an immune mediated source, is rare [69]. It was found that the severe and non-survivors patients have a lower platelet count compared to non-severe and the survivors, respectively [70, 71]. Accordingly, low platelet count in these patients may be due to platelet consumption and associated with the increased risk of mortality; however, it has not been determined as a predictor factor for this disease’s mortality [65, 71]. The patients with a temporal tendency to the decreased platelet count may experience a worsening thrombotic complication and lower nadir platelet counts are related to the increased mortality rate [69, 72].

In viral infections, platelet’s activation may occur either by viral immune complexes or by host inflammatory responses, and the activated platelets are more cleared from circulation by the reticuloendothelial system macrophages [73]. Expression of ACE2, which is the direct receptor of SARS-CoV-2 spike protein on platelets, as well as the induction of platelet’s activation by anti-spike monoclonal antibody were recently reported [74]. A recent report has been shown that circulating platelets obtained from COVID-19 patients had a higher level of surface membranes of P-selectin expression compared to normal controls. Additionally, platelet’s aggregation was greater in patients responding to lower concentrations of platelet agonists [75].

Toll-like receptors, structures, functions, as well as its specific ligand and main role in thrombosis

TLRs are type I transmembrane glycoprotein (GP) receptors consisting of (i) 20–27 extracellular leucine-rich repeat (LRR) domains used for the recognition of PAMP/DAMP or VAMP, (ii) a transmembrane domain, and (iii) a cytosolic Toll/interleukin (IL)-1 receptor (TIR) domain used for the activation of downstream cell signaling pathways [76]. The extracellular domains of TLR contain glycan moieties serving as binding sites for ligands. Moreover, TLRs are classified according to their ligands and cellular localizations. Immune cells (including dendritic cells, macrophages, NK cells, T cells, and B cells) as well as non-immune cells (including epithelial and endothelial cells, and fibroblasts) express these receptors [77]. Notably, TLR-1, − 2, − 4, − 5, − 6, and 10 are primarily located at the cell surface, whereas TLR3, 7, 8, and 9 are present on the membranes of surrounding intracellular vesicles, including endosomes, lysosomes, and the endoplasmic reticulum that could recognize pathogenic nucleic acids [8, 78].

Furthermore, TLR can be sub-classified based on sequence analysis and three-dimensional structures into three-domain (TLR-1, − 2, − 4, − 6, − 10) and single-domain (TLR-3, − 5, − 7, − 8, − 9) TLRs [76]. In this regard, the single-domain and three-domain TLRs interact with hydrophilic ligands like nucleic acids, and lipid-containing molecules such as LPS and lipoproteins respectively [79]. Platelet’s activation can up regulate TLR-2, TLR-4, and TLR-9 expressions in these cells [23, 80, 81]. As well, in mice, TLR2 ligands can alter megakaryocyte TLRs expression [82]. Platelets express some functional chemokine receptors such as CCR1, 3, 4, and CXCR4, which are involved in infection, hemostasis, inflammation, and even in the development of atherosclerosis (Fig. 3) [42].

Fig. 3
figure 3

Toll-like receptor (TLR) signaling pathways and involved effector molecules. TLR 1, 2, 4, 5, and 6 are in homodimer or heterodimer forms are located on the cell surfaces, when stimulated by PAMPs, MyD88 interacts with IRAK-4 MyD88-IRAK-4 complex, recruits IRAK-1 and IRAK-2, resulting in the phosphorylation of IRAKs. Phosphorylated IRAKs leave MyD88 after and interact with TRAF6. TRAF6 induces the activation of TAK-1 and TAB2/3 then activation of IκB and MAPK occurs. The activation of IκB and MAPK result in the subsequent translocation of AP1 and NFkB to nucleus. TLR3, 7, 8, and 9 are located on the endosomal membrane. Stimulation of endosomal TLRs leads to the recruitment of MyD88, IRAK4, IRAK1, and TRAF6 and the translocation of IRF7 to nucleusTLR3 and part of TLR4 use TRIF as their adaptor. The interaction of TRIF with RIP1 leads to RIP1 polyubiquitination and their combination with TAB2 and TAB3, result in the translocation of NF-κB and AP-1 nucleus. The nuclear translocation of transcription factors including the NFκB in early and late stages (all TLRs), AP-1 (all except TLR 3), the IRF-3 (TLR3 and TLR4) and IRF-7 (TLR7/8/9) occur. These pathways lead to inflammatory cytokine synthesis, secretion in the case of platelets and the production type 1 IFNs [84, 85]

A recent study revealed that SARS-CoV-2 mRNAs encoding NSP10, E-protein, NSP8, and S2, have strong binding affinities toward intracellular TLR3, TLR7, TLR8, and TLR9, respectively [83]. Additionally, it was shown that SARS-CoV-2 spike protein could interact with TLR4, and TLR-4 activation plays a major role in inflammatory response in COVID-19 infection.

NOD2 -related platelet activation and thrombosis

Among the main families of pattern recognition receptors, Toll-like receptors and nucleotide-binding oligomerization domain (NOD)–like receptors are the critical receptors in innate immunity response. NODs are cytoplasmic receptors. NOD1 and NOD2 are the two important NODs, NOD1 and NOD2 contains 1 and 2 caspase recruitment domain respectively [86]. NOD2 is mainly expressed in monocytes, macrophages, dendritic cells, intestinal epithelial cells, and paneth cells whereas NOD1 has a wide distribution. NODs have a major role in innate immune response against infections. In bacterial and viral infections NOD2 through the activation of NF-κB, MAPK and caspase-1 pathways, lead to increase expression of proinflammatory cytokines, including IL-1β, tumor necrosis factor-alpha (TNFα), IL-6, IL-12p40, CC-chemokine ligand 2, IL-8, CXC-chemokine ligand 2 and various antimicrobial agents such as defensins. The NOD2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes [87]. NOD2 receptor activation induces platelet production of IL-1β as proinflammatory cytokines [5]. NOD2 as a cytoplasmic viral PRR trigger the activation of interferon-regulatory factor 3 (IRF3) and production of interferon-β (IFN-β). After recognition of a viral ssRNA genome, NOD2 used the adaptor protein mitochondrial antiviral signaling (MAVS) to activate IRF3 and innate immune antiviral response [91]. Similar functions of NOD2 are observed in response to influenza A and parainfluenza viruses [88, 89]. Platelets express NOD2 that potentiates platelet activation and enhances in vivo thrombosis [90]. The crucial role of platelets in thrombosis, hemostasis, and immune response, studies in activation of NOD2 in SARS-CoV-2 infection could showed new insight into the pathogenesis and treatment of inflammation and thrombotic complications in COVID-19 disease.

Platelets immunomodulatory functions

Platelet indicates cellular immunomodulatory functions via having interactions with endothelial cells and leukocytes and responses to infection. Accordingly, these responses may consequently enhance vascular inflammation and induce thrombosis [92, 93]. Previous studies have shown that by considering the presence of TLR-1, − 2, − 4, − 6, and TLR-7 at the membrane and intracellular of platelet, their expressions depend on the status of platelet’s activation [22,23,24]. TLR-1,-6 in infection situation is responsible for generating pro-inflammatory platelets’ interaction with leukocytes, including neutrophils, monocytes, eosinophils, and dendritic cells that, as innate immune mediated cells, can accelerate platelet’s aggregation [47]. Circulating platelets contain a functional spliceosome, particularly endogenous pre-mRNAs as well as small nuclear ribonucleoproteins [94,95,96]. During platelet’s activation, splices introns from interleukin 1-β or tissue factor (TF) pre-mRNAs in platelet cytoplasm can be translated into proteins [97, 98]. In this regard, TF overexpression in platelet and monocyte may be related to thrombosis in COVID-19 [99]. During the platelet activation, growth factor cytokines, chemokines, and molecules such as sCD40L, are released. Platelet is the primary source of sCD40L in circulation that plays a critical role in thrombosis and initiating both innate and adaptive immunities [23, 100]. Additionally, platelets express some functional chemokine receptors such as CCR1, 3, 4, and CXCR4, which are involved in infection, hemostasis, inflammation, and even in the development of atherosclerosis. A previously performed study has shown that sCD62P is increases in ARDS patients and in severe and non-survivors compared with non-severe cases and survivors, respectively [37,38,39]. Therefore, future discoveries related to the immune-mediated activation platelet are necessary to guide the type of therapies needed to control both thrombosis and coagulopathies, particularly in severely ill COVID-19 patients.

Inhibitors of TLRs and P-selectin

TLRs antagonists include monoclonal antibodies, bacterial-derived proteins, natural or synthetic small molecules. TLR3, TLR7, and TLR8 antagonists can be used against viral infections. Among TLRs, TLR4 is a remarkable pattern recognition receptor recognizes multiple PAMPs of bacteria, viruses, and other pathogens and DAMPs from host lytic cells. Several drugs have been demonstrated to have inhibitory effects on the TLR4 pathways. TLR4 antagonist FP7 significantly decreased the cytokine production in response to lethal lipopolysaccharide (LPS) used in the influenza infection [101]. Eritoran and Tak242 as TLR4 antagonists were developed for the treatment of severe sepsis. TAK-242 (Resatorvid) reduce signaling and inflammation by blocks the interaction between TLR4 and the adaptor proteins TIRAP and TRAM [102]. TAK-242 has pre-clinical success but in clinical investigations the results are not promising. In a phase III trial in managing of severe sepsis, serum cytokine levels suppression of IL-6, IL-8, and TNF-훼 compared to the placebo group have not been shown [103]. Recently, a novel inhibitory activity of angiotensin II receptor blockers (ARBs), and statins on TLR2 and TLR4 signaling was discovered. Valsartan (from the ARB family) has been demonstrated to decrease proinflammatory cytokine release and infarct size by inhibiting TLR4 signaling. Among statins family, Atorvastatin, Fluvastatin, Simvastatin has all shown an inhibitory effect on the reduction in vascular inflammation and the TLR4 signaling and pathway [104,105,106]. Eritoran (E5564) and TAK-242 are currently undergoing phase III clinical trials, especially for severe sepsis. In septic cases with in the high-dose treatment of eritoran a 12% reduction in the mortality rate compared to placebo was demonstrated [107]. Eritoran blocked DAMP accumulation and attenuated influenza virus-induced acute lung injury [108].

Anti P-selectin monoclonal antibodies or P-selectin antagonist reduces the risk of inflammation and thrombosis [109]. Inclacumab a novel and recombinant monoclonal antibody against P-selectin, block the P-selectin- PSGL-1 mediated cell adhesion. Inclacumab is a human IgG4 monoclonal antibody has anti-cell adhesion effects and the potential of anti-inflammatory, antithrombotic, and antiatherogenic properties [110,111,112]. Recently crizanlizumab, a human IgG2 anti-P-selectin antibody, approved by FDA. Crizanlizumab reduce vaso-occlusive crises (VOCs) in sickle cell disease patients [113]. These P-selectin antagonists may have benefits to inhibit of platelet-leukocyte-endothelial interactions in COVID-19 patients and reduce the thrombosis complications induced by SARS-COV2 infection.


Severe SARS-CoV-2 infection mostly presents with coagulation abnormalities, pulmonary microvascular thrombosis, and severe inflammatory response [114]. Thrombosis complications are common among critically ill COVID-19 patients, and these also increase the risk of some life-threatening complications such as myocardial infarction and ARDS [40, 41]. Although the mechanisms of thrombosis in SARS-CoV-2 infection are still unclear, platelet’s activation and inflammatory responses may contribute in this process [42]. TLRs could bind to the specific ligands and then result in the activation of the inflammatory cascades. As well, platelet can be activated by TLRs, and in addition, inflammatory mediators such as LPS and TNF-ɑ may induce P-selectin expression [16, 84]. P-selectin, as a platelet’s activation marker, plays central roles in leukocyte recruitment and expression of TF by monocyte, which is the activator of extrinsic coagulation cascade [43]. Both platelet’s activation and aggregation play critical roles in the pathogenesis of tissue damages such as acute myocardial infarction (AMI) and myocardial ischemia injury [115, 116]. Additionally, local release of DAMPs during the process of AMI is known to trigger proinflammatory TLRs activation, which consequently leads to the aggravation of myocardial injury [19, 20]. It is possible that the alternative platelet activation pathways, which are not targeted by currently available anti-platelet agents, may promote recurrent thrombosis in these settings [117].

SARS-CoV-2 -spike protein attachment to ACE2 on endothelial cells, platelets, and other target cells, triggers the pathogenesis of COVID-19 infection [25, 83]. Previous studies have found that the spike protein could bind to extracellular domains of TLRs, including TLR-1,-4,-6 [25]. Moreover, it has been proposed that the spike protein have a strong affinity with TLR4. Accordingly, TLR4 is mainly present at the surface cell membrane and it recognizes viral proteins before their entrance into the cell and also into the endosomal membrane [118]. TLR4 signaling is important in initiating inflammatory responses, and its overexpression can also lead to hyper inflammation reactions [119,120,121]. Regarding the fact that platelet could express TLR-4, it may play significant roles in both platelet’s activation and thrombosis. As well, Platelet overexpression of P-selectin in severe SARS-CoV-2 patients suggests a central role of platelet’s activation as a part of the pathogenic mechanism of COVID-19 leading to the production of pulmonary thrombi. So, the administration of anti P-selectin antibody like Crizanlizumab or inclacumab may be helpful for the severe cases. In this regard, a rapid investigation is required to determine the pathways that mostly contribute to platelet’s activation, because these may be important in reducing the rates of morbidity and mortality caused by COVID-19 infection. Among the alternative pathways, TLRs related thrombosis may play a more critical role in COVID-19 complex pathophysiology. In this regard, further studies are required to determine the role of TLRs in the mechanisms of thrombosis and coagulopathies associated with COVID-19 infection. In addition, the administrations of anti-P selectin monoclonal antibody and TLRs antagonist may reduce the cytokine storm, thrombosis, and mortality in COVID-19 patients. More studies are needed to investigate the clinical significance of both TLRs upregulation and antagonist in COVID-19-related thrombosis.

Availability of data and materials

Not applicable.



severe acute respiratory syndrome coronavirus 2


coronavirus disease


toll-like receptors


pathogen-associated molecular patterns


tissue factor


  1. 1.

    Lin E, Freedman JE, Beaulieu LM. Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases. Cardiovasc Ther. 2009;27(2):117–23.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Seyoum M, Enawgaw B, Melku M. Human blood platelets and viruses: defense mechanism and role in the removal of viral pathogens. Thromb J. 2018;16(1):1–6.

    Article  Google Scholar 

  3. 3.

    Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, et al. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol. 2006;80(18):8951–60.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Cloutier N, Allaeys I, Marcoux G, Machlus KR, Mailhot B, Zufferey A, et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proc Natl Acad Sci. 2018;115(7):E1550–E9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Zhang S, Zhang S, Hu L, Zhai L, Xue R, Ye J, et al. Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis. Circulation. 2015;131(13):1160–70.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Dib PRB, Quirino-Teixeira AC, Merij LB, Pinheiro MBM, Rozini SV, Andrade FB, et al. Innate immune receptors in platelets and platelet-leukocyte interactions. J Leukoc Biol. 2020;108(4):1157–82.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Clemetson KJ, Clemetson JM. Platelet Receptors. In: Platelet receptors. Platelets: Elsevier; 2019. p. 169–92.

    Chapter  Google Scholar 

  8. 8.

    Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21(1):335–76.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity. 2010;32(3):305–15.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Lien E, Ingalls RR. Toll-like receptors. Crit Care Med. 2002;30(1):S1–S11.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Moresco EMY, LaVine D, Beutler B. Toll-like receptors. Curr Biol. 2011;21(13):R488–R93.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Blair P, Rex S, Vitseva O, Beaulieu L, Tanriverdi K, Chakrabarti S, et al. Stimulation of toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res. 2009;104(3):346–54.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Rivadeneyra L, Carestia A, Etulain J, Pozner RG, Fondevila C, Negrotto S, et al. Regulation of platelet responses triggered by toll-like receptor 2 and 4 ligands is another non-genomic role of nuclear factor-kappaB. Thromb Res. 2014;133(2):235–43.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Zhang G, Han J, Welch EJ, Richard DY, Voyno-Yasenetskaya TA, Malik AB, et al. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol. 2009;182(12):7997–8004.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol. 2014;32(1):461–88.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Banerjee M, Huang Y, Joshi S, Popa GJ, Mendenhall MD, Wang QJ, et al. Platelets endocytose viral particles and are activated via TLR (toll-like receptor) signaling. Arterioscler Thromb Vasc Biol. 2020;40(7):1635–50.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351(25):2611–8.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Jayachandran M, Brunn GJ, Karnicki K, Miller RS, Owen WG, Miller VM. In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J Appl Physiol. 2007;102(1):429–33.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Arumugam TV, Okun E, Tang S-C, Thundyil J, Taylor SM, Woodruff TM. Toll-like receptors in ischemia-reperfusion injury. Shock. 2009;32(1):4–16.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006;114(1):I-270–I-4.

    Google Scholar 

  21. 21.

    Kreutz R, Bliden K, Tantry U, Gurbel P. Viral respiratory tract infections increase platelet reactivity and activation: an explanation for the higher rates of myocardial infarction and stroke during viral illness. J Thromb Haemost. 2005;3(9):2108–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Shiraki R, Inoue N, Kawasaki S, Takei A, Kadotani M, Ohnishi Y, et al. Expression of toll-like receptors on human platelets. Thromb Res. 2004;113(6):379–85.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O. Evidence of toll-like receptor molecules on human platelets. Immunol Cell Biol. 2005;83(2):196–8.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Aslam R, Speck ER, Kim M, Crow AR, Bang KA, Nestel FP, et al. Platelet toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo. Blood. 2006;107(2):637–41.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020;92(10):2105–13.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Gironella M, Molla M, Salas A, Soriano A, Sans M, Closa D, et al. The role of P-selectin in experimental colitis as determined by antibody immunoblockade and genetically deficient mice. J Leukoc Biol. 2002;72(1):56–64.

    CAS  PubMed  Google Scholar 

  27. 27.

    Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989;59(2):305–12.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Geng J-G, Bevilacquat MP, Moore KL, Mclntyre TM, Prescott SM, Kim JM, et al. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature. 1990;343(6260):757–60.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    McEver R. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells. 1990;16(1):73–80; discussion.

  30. 30.

    Celi A, Lorenzet R, Furie B, Furie BC, editors. Platelet-leukocyte-endothelial cell interaction on the blood vessel wall. Seminars in hematology; 1997.

  31. 31.

    Pan J, Xia L, McEver RP. Comparison of promoters for the murine and human P-selectin genes suggests species-specific and conserved mechanisms for transcriptional regulation in endothelial cells. J Biol Chem. 1998;273(16):10058–67.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Hahne M, Jäger U, Isenmann S, Hallmann R, Vestweber D. Five tumor necrosis factor-inducible cell adhesion mechanisms on the surface of mouse endothelioma cells mediate the binding of leukocytes. J Cell Biol. 1993;121(3):655–64.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Liu Z, Miner JJ, Yago T, Yao L, Lupu F, Xia L, et al. Differential regulation of human and murine P-selectin expression and function in vivo. J Exp Med. 2010;207(13):2975–87.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Panés J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol. 1999;126(3):537–50.

    Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell. 1993;74(3):541–54.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie B, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci. 1994;91(19):8767–71.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Mulligan MS, Polley MJ, Bayer RJ, Nunn MF, Paulson J, Ward PA. Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest. 1992;90(4):1600–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Agrati C, Bordoni V, Sacchi A, Petrosillo N, Nicastri E, Del Nonno F, et al. Elevated P-Selectin in severe Covid-19: considerations for therapeutic options. Med J Hematol Infectious Diseases. 2021;13(1).

  39. 39.

    Neri T, Nieri D, Celi A. P-selectin blockade in COVID-19-related ARDS. Am J Phys Lung Cell Mol Phys. 2020;318(6):L1237–L8.

    CAS  Article  Google Scholar 

  40. 40.

    Klok F, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Kauskot A, Hoylaerts MF. Platelet receptors. Antiplatelet Agents. 2012:23–57.

  42. 42.

    Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood J Am Soc Hem. 2000;96(13):4046–54.

    CAS  Google Scholar 

  43. 43.

    Boukour S, Massé JM, Benit L, Dubart-Kupperschmitt A, Cramer E. Lentivirus degradation and DC-SIGN expression by human platelets and megakaryocytes. J Thromb Haemost. 2006;4(2):426–35.

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Flaujac C, Boukour S, Cramer-Bordé E. Platelets and viruses: an ambivalent relationship. Cell Mol Life Sci. 2010;67(4):545–56.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Koupenova M, Vitseva O, MacKay CR, Beaulieu LM, Benjamin EJ, Mick E, et al. Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. Blood J Am Soc Hem. 2014;124(5):791–802.

    CAS  Google Scholar 

  46. 46.

    Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564–81.

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Koenen RR. The prowess of platelets in immunity and inflammation. Thromb Haemost. 2016;116(10):605–12.

    Article  Google Scholar 

  48. 48.

    Panigrahi S, Ma Y, Hong L, Gao D, West XZ, Salomon RG, et al. Engagement of platelet toll-like receptor 9 by novel endogenous ligands promotes platelet hyperreactivity and thrombosis. Circ Res. 2013;112(1):103–12.

    CAS  Article  PubMed  Google Scholar 

  49. 49.

    Koupenova M, Mick E, Mikhalev E, Benjamin EJ, Tanriverdi K, Freedman JE. Sex differences in platelet toll-like receptors and their association with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2015;35(4):1030–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Rex S, Beaulieu LM, Perlman DH, Vitseva O, Blair PS, McComb ME, et al. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and α-granule release. Thromb Haemost. 2009;102(07):97–110.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    O'neill LA, Golenbock D, Bowie AG. The history of toll-like receptors—redefining innate immunity. Nat Rev Immunol. 2013;13(6):453–60.

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Scherlinger M, Sisirak V, Richez C, Lazaro E, Duffau P, Blanco P. New insights on platelets and platelet-derived microparticles in systemic lupus erythematosus. Curr Rheumatol Rep. 2017;19(8):1–10.

    CAS  Article  Google Scholar 

  53. 53.

    D'Atri LP, Etulain J, Rivadeneyra L, Lapponi MJ, Centurion M, Cheng K, et al. Expression and functionality of toll-like receptor 3 in the megakaryocytic lineage. J Thromb Haemost. 2015;13(5):839–50.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Anabel A-S, Eduardo P-C, Antonio H-CP, Carlos S-M, Juana N-M, Honorio T-A, et al. Human platelets express toll-like receptor 3 and respond to poly I: C. Hum Immunol. 2014;75(12):1244–51.

    CAS  Article  PubMed  Google Scholar 

  55. 55.

    Jia S-J, Niu P-P, Cong J-Z, Zhang B-K, Zhao M. TLR4 signaling: a potential therapeutic target in ischemic coronary artery disease. Int Immunopharmacol. 2014;23(1):54–9.

    CAS  Article  PubMed  Google Scholar 

  56. 56.

    Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood J Am SocHematol. 2011;118(7):1952–61.

    CAS  Article  Google Scholar 

  57. 57.

    Mogensen TH, Paludan SR. Reading the viral signature by toll-like receptors and other pattern recognition receptors. J Mol Med. 2005;83(3):180–92.

    CAS  Article  PubMed  Google Scholar 

  58. 58.

    Turner NA. Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs). J Mol Cell Cardiol. 2016;94:189–200.

    CAS  Article  PubMed  Google Scholar 

  59. 59.

    Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood J Am Soc Hem. 2011;118(13):3708–14.

    CAS  Google Scholar 

  60. 60.

    Weyrich AS, Zimmerman GA. Platelets in lung biology. Annu Rev Physiol. 2013;75(1):569–91.

    CAS  Article  PubMed  Google Scholar 

  61. 61.

    Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006;116(12):3211–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Nemmar A, Hoet P, Vandervoort P, Dinsdale D, Nemery B, Hoylaerts M. Enhanced peripheral thrombogenicity after lung inflammation is mediated by platelet–leukocyte activation: role of P-selectin. J Thromb Haemost. 2007;5(6):1217–26.

    CAS  Article  PubMed  Google Scholar 

  63. 63.

    Sugiyama MG, Gamage A, Zyla R, Armstrong SM, Advani S, Advani A, et al. Influenza virus infection induces platelet-endothelial adhesion which contributes to lung injury. J Virol. 2016;90(4):1812–23.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Hottz ED, Bozza FA, Bozza PT. Platelets in immune response to virus and immunopathology of viral infections. Frontiers in medicine. 2018;5:121.

    Article  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao S, et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets. 2020;31(4):490–6.

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Zhang Y, Zeng X, Jiao Y, Li Z, Liu Q, Ye J, et al. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thromb Res. 2020;193:110–5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  67. 67.

    W-j G, Z-y N, Hu Y, W-h L, C-q O, J-x h, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

    Article  Google Scholar 

  68. 68.

    Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1469–72.

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88(1):14–26.

    Article  Google Scholar 

  70. 70.

    Li Q, Cao Y, Chen L, Wu D, Yu J, Wang H, et al. Hematological features of persons with COVID-19. Leukemia. 2020;34(8):2163–72.

    CAS  Article  PubMed  Google Scholar 

  71. 71.

    Jiang SQ, Huang QF, Xie WM, Lv C, Quan XQ. The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants. Br J Haematol. 2020;190(1):e29–33.

    CAS  Article  PubMed  Google Scholar 

  72. 72.

    Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6.

    CAS  Article  PubMed  Google Scholar 

  73. 73.

    Assinger A. Platelets and infection–an emerging role of platelets in viral infection. Front Immunol. 2014;5:649.

    Article  Google Scholar 

  74. 74.

    Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020;13(1):1–22.

    Article  Google Scholar 

  75. 75.

    Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene expression and function in patients with COVID-19. Blood J Am Soc Hem. 2020;136(11):1317–29.

    CAS  Google Scholar 

  76. 76.

    Kang JY, Lee J-O. Structural biology of the toll-like receptor family. Annu Rev Biochem. 2011;80(1):917–41.

    CAS  Article  PubMed  Google Scholar 

  77. 77.

    Delneste Y, Beauvillain C, Jeannin P. Innate immunity: structure and function of TLRs. Medecine Sciences: M/S. 2007;23(1):67–73.

    Article  Google Scholar 

  78. 78.

    Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11(5):373–84.

    CAS  Article  PubMed  Google Scholar 

  79. 79.

    Jin MS, Lee J-O. Structures of TLR–ligand complexes. Curr Opin Immunol. 2008;20(4):414–9.

    CAS  Article  PubMed  Google Scholar 

  80. 80.

    Tsai J-C, Lin Y-W, Huang C-Y, Lin C-Y, Tsai Y-T, Shih C-M, et al. The role of calpain-myosin 9-Rab7b pathway in mediating the expression of toll-like receptor 4 in platelets: a novel mechanism involved in α-granules trafficking. PLoS One. 2014;9(1):e85833.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  81. 81.

    Thon JN, Peters CG, Machlus KR, Aslam R, Rowley J, Macleod H, et al. T granules in human platelets function in TLR9 organization and signaling. J Cell Biol. 2012;198(4):561–74.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  82. 82.

    Beaulieu LM, Lin E, Morin KM, Tanriverdi K, Freedman JE. Regulatory effects of TLR2 on megakaryocytic cell function. Blood J Am Soc Hem. 2011;117(22):5963–74.

    CAS  Google Scholar 

  83. 83.

    Choudhury A, Chandra Das N, Patra R, Mukherjee S. In silico analyses on the comparative sensing of SARS-CoV-2 mRNA by the intracellular TLRs of human. J Med Virol. 2020.

  84. 84.

    Du B, Jiang Q-L, Cleveland J, Liu B-R, Zhang D. Targeting toll-like receptors against cancer. J Cancer Metastasis and Treatment. 2016;2(12):463–70.

    CAS  Article  Google Scholar 

  85. 85.

    Cognasse F, Nguyen KA, Damien P, McNicol A, Pozzetto B, Hamzeh-Cognasse H, et al. The inflammatory role of platelets via their TLRs and Siglec receptors. Front Immunol. 2015;6:83.

    Article  Google Scholar 

  86. 86.

    Negroni A, Pierdomenico M, Cucchiara S, Stronati L. NOD2 and inflammation: current insights. J Inflamm Res. 2018;11:49–60.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  87. 87.

    Beynon V, Cotofana S, Brand S, Lohse P, Mair A, Wagner S, et al. NOD2/CARD15 genotype influences MDP-induced cytokine release and basal IL-12p40 levels in primary isolated peripheral blood monocytes. Inflamm Bowel Dis. 2008;14(8):1033–40.

    Article  PubMed  Google Scholar 

  88. 88.

    Kanneganti T-D. Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol. 2010;10(10):688–98.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  89. 89.

    Keestra-Gounder AM, Tsolis RM. NOD1 and NOD2: beyond peptidoglycan sensing. Trends Immunol. 2017;38(10):758–67.

    CAS  Article  PubMed  Google Scholar 

  90. 90.

    Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278(11):8869–72.

    CAS  Article  PubMed  Google Scholar 

  91. 91.

    Sabbah A, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol. 2009;10(10):1073–80.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  92. 92.

    Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114(09):449–58.

    Article  Google Scholar 

  93. 93.

    Koupenova M, Clancy L, Corkrey HA, Freedman JE. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res. 2018;122(2):337–51.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  94. 94.

    Shashkin PN, Brown GT, Ghosh A, Marathe GK, McIntyre TM. Lipopolysaccharide is a direct agonist for platelet RNA splicing. J Immunol. 2008;181(5):3495–502.

    CAS  Article  PubMed  Google Scholar 

  95. 95.

    Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell. 2005;122(3):379–91.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  96. 96.

    Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood J Am Soc Hem. 2011;117(19):5189–97.

    CAS  Google Scholar 

  97. 97.

    Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol. 2001;154(3):485–90.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  98. 98.

    Hr S, Tolley ND, Foulks JM, Denis MM, Risenmay BW, Buerke M, et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets. J Exp Med. 2006;203(11):2433–40.

    Article  Google Scholar 

  99. 99.

    Eslamifar Z, Behzadifard M, Soleimani M, Behzadifard S. Coagulation abnormalities in SARS-CoV-2 infection: overexpression tissue factor. Thromb J. 2020;18(1):1–4.

    Article  Google Scholar 

  100. 100.

    Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol. 2005;238(1):1–9.

    CAS  Article  PubMed  Google Scholar 

  101. 101.

    Perrin-Cocon L, Aublin-Gex A, Sestito SE, Shirey KA, Patel MC, André P, et al. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci Rep. 2017;7(1):1–13.

    Article  Google Scholar 

  102. 102.

    Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (resatorvid), a small-molecule inhibitor of toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol. 2011;79(1):34–41.

    CAS  Article  PubMed  Google Scholar 

  103. 103.

    Rice TW, Wheeler AP, Bernard GR, Vincent J-L, Angus DC, Aikawa N, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med. 2010;38(8):1685–94.

    CAS  Article  PubMed  Google Scholar 

  104. 104.

    Gao W, Xiong Y, Li Q, Yang H. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics. Front Physiol. 2017;8:508.

    Article  PubMed  PubMed Central  Google Scholar 

  105. 105.

    Koushki K, Shahbaz SK, Mashayekhi K, Sadeghi M, Zayeri ZD, Taba MY, et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2021;60(2):175–99.

    CAS  Article  PubMed  Google Scholar 

  106. 106.

    Yang M, Diao Z, Wang Z, Yan G, Zhao G, Zheng M, et al. Pravastatin alleviates lipopolysaccharide-induced placental TLR4 over-activation and promotes uterine arteriole remodeling without impairing rat fetal development. J Biomed Res. 2018;32(4):288–97.

    Article  PubMed  PubMed Central  Google Scholar 

  107. 107.

    Wickelgren I. Targeting the tolls. American Association for the Advancement of Science; 2006.

    Google Scholar 

  108. 108.

    Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 2013;497(7450):498–502.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  109. 109.

    Myers DD, Schaub R, Wrobleski SK, Londy FJ, Fex BA, Chapman AM, et al. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost. 2001;85(03):423–9.

    CAS  Article  Google Scholar 

  110. 110.

    Schmitt C, Abt M, Ciorciaro C, Kling D, Jamois C, Schick E, et al. First-in-man study with inclacumab, a human monoclonal antibody against P-selectin. J Cardiovasc Pharmacol. 2015;65(6):611–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  111. 111.

    Tardif J-C, Tanguay J-F, Wright SR, Duchatelle V, Petroni T, Grégoire JC, et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non–ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013;61(20):2048–55.

    CAS  Article  PubMed  Google Scholar 

  112. 112.

    Geng X, Mihaila R, Yuan Y, Strutt S, Benz J, Tang T, et al., editors. Inclacumab, a fully human anti-p-selectin antibody, directly binds to PSGL-1 binding region and demonstrates robust and durable inhibition of cell adhesion. Blood; 2020: AMER SOC HEMATOLOGY 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA.

  113. 113.

    Maitra P, Caughey M, Robinson L, Desai PC, Jones S, Nouraie M, et al. Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica. 2017;102(4):626.

    Article  Google Scholar 

  114. 114.

    Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559–61.

    CAS  Article  PubMed  Google Scholar 

  115. 115.

    Gawaz M, Neumann F-J, Ott I, Schiessler A, Schömig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996;93(2):229–37.

    CAS  Article  PubMed  Google Scholar 

  116. 116.

    Xu Y, Huo Y, Toufektsian M-C, Ramos SI, Ma Y, Tejani AD, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Phys Heart Circ Phys. 2006;290(2):H692–H9.

    CAS  Article  Google Scholar 

  117. 117.

    Hally KE, La Flamme AC, Larsen PD, Harding SA. Platelet toll-like receptor (TLR) expression and TLR-mediated platelet activation in acute myocardial infarction. Thromb Res. 2017;158:8–15.

    CAS  Article  PubMed  Google Scholar 

  118. 118.

    Kuzmich NN, Sivak KV, Chubarev VN, Porozov YB, Savateeva-Lyubimova TN, Peri F. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines. 2017;5(4):34.

    CAS  Article  PubMed Central  Google Scholar 

  119. 119.

    Molteni M, Gemma S, Rossetti C. The role of toll-like receptor 4 in infectious and noninfectious inflammation. Mediat Inflamm. 2016;2016:1–9.

    CAS  Article  Google Scholar 

  120. 120.

    Patra MC, Shah M, Choi S, editors. Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. Seminars in cancer biology; 2020: Elsevier.

  121. 121.

    Roshan MH, Tambo A, Pace NP. The role of TLR2, TLR4, and TLR9 in the pathogenesis of atherosclerosis. Int J Inflamm. 2016;2016:1–11.

    CAS  Article  Google Scholar 

Download references


Not applicable.


Not applicable.

Author information




All Authors contributed to write the paper and approved the final manuscript.

Corresponding author

Correspondence to Mahin Behzadi Fard.

Ethics declarations

Ethics approval and consent to participate

As the current study was a review, there was no ethics committee to approve the study.

Consent for publication

All authors have consent to publication.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fard, M.B., Fard, S.B., Ramazi, S. et al. Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity. Thrombosis J 19, 59 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • SARS-CoV-2
  • COVID-19
  • Thrombosis
  • TLRs
  • Platelet activation
  • PAMPs
  • Proinflammatory cytokines